{"id":"NCT02798120","sponsor":"Novan, Inc.","briefTitle":"P3 Long Term Safety Study of Once Daily SB204 in Acne","officialTitle":"A Phase 3 Multi-Center, Open Label Study Evaluating the Long Term Safety of SB204 Once Daily in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-12","primaryCompletion":"2017-04","completion":"2017-04-27","firstPosted":"2016-06-14","resultsPosted":"2023-05-12","lastUpdate":"2023-05-12"},"enrollment":601,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"SB204 4%","otherNames":["NVN1000"]}],"arms":[{"label":"SB204 4%","type":"EXPERIMENTAL"}],"summary":"This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.","primaryOutcome":{"measure":"Number of Subjects With Adverse Events Ongoing From Parent Study at Start of Study NI-AC303)","timeFrame":"Baseline","effectByArm":[{"arm":"SB204 Experienced","deltaMin":59,"sd":null},{"arm":"SB204 Naive","deltaMin":62,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":69,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":296},"commonTop":["Nasopharyngitis","Application site dryness","Application site pruritus","Headache","Influenza"]}}